Introduction
The increased rate of uncorrected replication errors at simple repeat sequences is commonly known as microsatellite instability (MSI). This type of widespread genome instability was initially observed in tumors arising in hereditary nonpolyposis colorectal cancer (HNPCC) patients (Aaltonen et al., 1993; Ionov et al., 1993; Parsons et al., 1993; Thibodeau et al., 1993) . The majority of HNPCC patients bear mutation in one of the mismatch repair (MMR) genes leading to the defective repair of repetitive sequences (Peltomaki, 2001 ). An identical genetic instability is also featured by 10-15% of colorectal, gastric and endometrial sporadic carcinomas. In this case, the impaired expression of specific MMR genes due to epigenetic modifications (such as MLH1 promoter methylation) is most often responsible for the repair defect (Peltomaki, 2001) . Inactivation of MMR genes is in turn responsible for the accumulation of further genetic lesions occurring in coding repeats and eventually leading to frameshift mutations and expression of inactive proteins. Indeed, genes clearly involved in malignant transformation, such as TGFbRII, BAX or IGFRII (Markowitz et al., 1995; Souza et al., 1996; Rampino et al., 1997) , can be inactivated due to MSI. A large number of genes containing coding repeats were found to be affected by MSI and the list of potential target genes was further increased by the use of in silico genome-wide screenings (Kim et al., 2002; Mori et al., 2002; Park et al., 2002; Woerner et al., 2003) . However, the isolation of the real targets from the crowds of 'bystanders' awaits biological demonstration of their role in cancer development and progression (Boland et al., 1998; Zhang et al., 2001; .
Most human cancer feature other forms of genetic instability, and inactivation of many proteins involved in DNA repair were shown to play a significant role in tumorigenesis. Indeed, DNA double strand breaks (DSB) signaling molecules like ATM and CHK2 are mutated in both human cancer predisposing syndromes (Bell et al., 1999; Shiloh, 2003 ; Ataxia-Telangiectasia and Li-Fraumeni syndrome, respectively) and sporadic forms of cancer Schaffner et al., 2000; Matsuoka et al., 2001; Hangaishi et al., 2002) . The multiprotein MRE11/NBS1/RAD50 (MNR) complex plays a pivotal role in the cellular responses to DNA-DSB contributing to the activation of cell cycle checkpoints and DNA repair and thus favoring genomic stability (D'Amours and Jackson, 2002) . Impairment of its function through mutations of the NBS1 gene leads to the cancer-prone Nijmegen Breakage Syndrome (Carney et al., 1998) in humans, while NBS1-defective mice develop lymphoid tumors (Kang et al., 2002) . A mouse model expressing a hypomorphic RAD50 further demonstrated that destabilization of the MNR complex is an event predisposing to cancer (Bender et al., 2002) . In contrast, MRE11 involvement in cancer had been overlooked due to the lethal phenotype of the genetic KO in mice (Xiao and Weaver, 1997) and the paucity of A-T-like Disorder (AT-LD) cases, due to inherited mutations of the MRE11 gene . Few mutations of this gene have been described in human breast and lymphoid tumors (Fukuda et al., 2001) , but their biological effects have not been clarified yet. We recently identified a new mutation of human MRE11 leading to skipping of exon 5 and to the introduction of a premature stop codon in the assembly of a mutant MRE11 transcript, thereafter referred to as 484del88 transcript. This mutation is associated with a reduced expression of the three members of the MNR complex, with the inability to form ionizing radiationinduced nuclear foci (IRIF) and a defective intra-S checkpoint, thus suggesting that MNR complex function is impaired in MRE11 mutated cells (Giannini et al., 2002) . Exon 5 skipping is dependent on the specific mutation of a poly-T(11) repeat constituting the polypirimidine stretch/accessory splicing signal within MRE11 gene IVS-4, thereafter referred to as the poly(T)11. This genetic alteration was selectively found in MMR-defective, but not in MMR-proficient, cell lines. In order to study MRE11 mutation frequency as well as the relationships with its expression in human cancer, we have analysed 49 MMR-defective colorectal cancer (CRC) cases and other 21 MMR-defective primary tumors. We also addressed genotypephenotype correlations in this context and showed a stronger reduction of MRE11 expression in samples with two bases and biallelic shortening of the Poly(T)11.
Results

Variable shortening of the MRE11 poly(T)11 characterizes MSI-H colorectal cancer
In order to assess the frequency of mutation of the MRE11 poly(T)11, we examined a collection of 49 MMR-defective primary CRC cases and compared them with 14 endometrial, five ovarian, one ureter and one stomach MMR-defective primary tumors (Tables 1  and 2 ). By direct sequencing of the PCR fragment containing the MRE11 poly(T)11, we obtained a typical profile showing the 11 Ts (Figure 1a ) in more than 100 DNA extracted from normal tissues and/or MMRproficient colorectal primary cancer and cell lines. Variations from this profile, including a strong decrease or inversion of the ratio between the T and the A peak on the 11th or earlier positions in the repeat and the complete loss of 1 or more Ts, revealed the presence of a mutation (representative electropherograms are shown in Figure 1 ). In our series, shortening of the MRE11 poly(T)11 occurred in 41 colorectal cancers, seven endometrial cancers, one ovarian and one stomach cancer (Table 1) , and the statistical analysis indicated that the rate of the mutation is significantly different between colorectal cancer (83.7%) and the other tumor sites (Table 2 ). In most cases, the tumor DNAs displayed multiple poly(T) lengths either due to the presence of multiple alleles within the tumor area or to the persistence of contaminating non-neoplastic tissue (only in the cases where a T peak at the 11th position in the poly(T)11 was detected). In 17 CRC cases (34.6%) and in one endometrial and one ovarian cancer, we found a poly(T)9 allele (representative samples in Figure  1d -f), and in three CRC cases we also observed a poly(T)8 allele (not shown) indicative of two and three bases shortening, respectively. Furthermore, we failed to detect any wild-type poly(T)11 in 19 (38.8%), two (14.3%), and one (20%) colon, endometrial and ovarian cancers, respectively (Tables 1 and 2 ), indicating a very high incidence of biallelic mutation, especially in CRC. In contrast, we did not find shortening of the repeat in normal tissue and/or blood DNAs matching 40 of the 49 MMR-defective CRC samples (not shown).
Clinical-pathological correlations of MRE11 mutations
Although statistical significance was not obtained in most cases due to the relative paucity of cases in many figures, within the CRC series we found an association between MRE11 mutations and specific conventional clinical-pathological data, as reported in Table 3 . 
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Overall analysis indicated that the occurrence of MRE11 mutation was similar in the two sexes and among familial and sporadic cases, although the incidence of biallelic mutation appeared higher in familial (55.6%) compared to sporadic (29%) cases. Extremely high frequencies (94.7%) were associated to patients with advanced age at diagnosis. Interestingly, we observed that 100% of the patients with (A/B) stages at diagnosis had mutated MRE11, while the frequency of MRE11 mutation significantly decreased to 68.8% in patients with advanced (C or D) stage at diagnosis. Also, we noticed that 55.6% of the patient classified as grade 1 or 2 had a biallelic MRE11 mutation, and this contrasts with 33.3% of the G3 patients. As expected, most MMR-defective CRC we examined arose in the proximal colon. When the specific localization to cecum was studied, we noticed that five out of eight had mutated MRE11 accounting for 62.5% of these tumors, while up to 91.4% of the 35 patients with a noncecum proximal colonic localization showed mutated MRE11. Furthermore, only one (12.5%) of the tumors located in the cecum showed a bialleic mutation in contrast to 48.5% of those arising in other proximal colon locations. Consistent with published data (Kim et al., 2001; Park et al., 2002) , we also observed the occurrence of a monoallelic RAD50 mutation in 26% of our CRC cases. Interestingly, 69.2% of the RAD50 mutated cases also had the MRE11 mutation, while the same figure rose to 88.9 in RAD50 WT cases. In contrast, we found no differences when we compared MRE11 biallelic mutations in wild-type RAD50 versus mutated cases.
Variable shortening of the MRE11 poly(T)11differentially influences MRE11 expression
We have recently shown that shortening in the MRE11 poly(T)11 leads to impairment of the correct splicing process, generation of an aberrant MRE11 transcript containing a premature stop codon and impairment of the wild-type transcript formation causing a reduced expression of all the proteins of the MNR complex in a number of CRC cell lines (Giannini et al., 2002) . (Figure 2 ). This occurred even to a greater extent in the endometrial cancer AN3CA cells bearing homozygous poly(T)9 allele, suggesting that biallelic and two base pair deletions more strongly impair the MRE11 transcript expression and accumulation of the MNR complex components. To test whether mutations of the MRE11 poly(T)11 associate to an aberrantly spliced transcript and ultimately to impairment of wild-type MRE11 expression also in primary tumors, we analysed RNA extracted from the available bulk frozen CRC samples. Samples bearing a heterozygous poly(T)10/ (T)11 genotype (C313 and C469, not shown) demonstrated relatively high levels of MRE11 expression (Figure 3a) . In contrast, samples with a heterozygous poly(T)9/(T)10 genotype with no sign of wild-type poly(T)11 allele (C226 and C337, not shown) showed much lower levels of MRE11 (Figure 3a) . The electrophoretic analysis of the same PCR products after 45 amplification cycles showed only the wild-type MRE11 transcript in C313 and C469 (Figure 3b ). In contrast, we detected the mutant 484del88 transcript in the C226 and C337 samples (Figure 3b ), similar to AN3CA cells, confirming that the reduced wild-type MRE11 expression observed in these samples was due to impairment of the correct splicing.
MRE11 mutation impairs MRE11 and NBS1protein expression in primary CRC
To test whether impairment of MRE11 expression leads to impairment of MRE11 and NBS1 protein expression also in vivo, we looked at MRE11 and NBS1 protein expression on selected CRCs with mutations of the MRE11 poly(T)11, by immunohistochemistry. In all cases analysed, the normal tissue flanking the tumor area showed a clear nuclear staining of intestinal crypt cells (Figure 4a ) and smooth muscle cells of both the muscularis mucosae (Figure 4a ) and the bowel wall (Figure 4c ). The nuclei of stromal fibroblasts and inflammatory cells were also stained with the anti-MRE11 antibody (Figure 4a, c) . In contrast, we did not detect any staining in the neoplastic nuclei of the adenocarcinoma samples (Figure 4c ) and in the dysplastic cells of an adenomatous polyp (Figure 4b ). Similar results were obtained on a CRC liver metastasis (data not shown). On serial sections of the same samples we In contrast, we observed no or very faint staining on the neoplastic tissue of both the adenomatous polyp and the adenocarcinoma samples (Figure 5a-c) . Altogether, these results indicate that wild-type MRE11 transcript and protein expression are strongly impaired in MMRdeficient CRC primary cells with severe mutations of the MRE11 poly(T)11 and this might also affect the expression of the whole MNR complex.
Discussion
MMR-defective cells progressively accumulate replication errors in repeated sequences. By this means, frameshift mutations in coding regions may occur, causing inactivation of potential tumor suppressor genes that in turn may lead to cancer progression. However, not all the genes mutated through this mechanism are likely to be relevant for transformation and tumor progression, and it is acknowledged that the identification of the true 'targets' of the MMR defect relevant for carcinogenesis must be discriminated from the 'passenger' or 'bystander' mutations (Boland et al., 1998) . Despite the great consensus on the general matter, the definition of the minimal requirements to distinguish between target and passengers is far from being reached Perucho, 2003) . 
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We have recently proposed that human MRE11 might be a new target of inactivation in MMR-defective cancer (Giannini et al., 2002; Casorelli et al., 2003) . Interestingly, the replication error on MRE11 does not occur in its coding sequence, but in the poly(T)11 located within an accessory splicing signal in its IVS-4. As we demonstrated (Giannini et al., 2002 and the present paper), this leads to impairment, but not necessarily abolishment, of wild-type MRE11 expression and generation of an aberrant transcript missing exon 5 and potentially translating into an early truncated version of MRE11. Through a statistical approach, Duval et al. proposed that real targets should be mutated in more than 12% of the MMR-defective tumors, while lower frequencies are likely to be associated to bystanders due to the relatively high background of instability . We have shown that MRE11 mutations occur in 83.7% of MMR-defective primary CRCs, thus supporting the concept that they might be selected for an advantage in the carcinogenetic process. In total, 38.8% of the CRC cases had biallelic mutations, and thus impairment of the splicing of MRE11 precursor transcript from both alleles. Furthermore, 34.6% of the CRC and 27% of the whole MMR-defective cancer series showed deletion of at least two bases on the poly(T). These mutations are certainly associated with little production of wild-type MRE11 transcript and protein in cultured MMRdefective cells. By histochemistry, we have also shown that MRE11 expression is undetectable and/or strongly reduced in MMR-defective and MRE11 mutated primary tumor cells compared to normal intestinal mucosa or to stromal and infiltrating cells. Thus, a high incidence of severe and biallelic MRE11 mutations might be suggestive of a pressure towards the selection of a stronger impairment of its expression in cancer cells. In AT-LD and CRC cells, impairment of MRE11 protein expression also interferes with NBS1 and RAD50 accumulation in vitro Giannini et al., 2002) . Indeed, we found impaired NBS1 protein expression in primary CRCs defective for MRE11 accumulation, thus confirming that MRE11 is required for the correct assembly and stability of the MNR complex also in vivo. Reduced expression of both MRE11 and NBS1 is likely to result in the impairment of the MNR complex activities, as we previously reported the absence of MRE11 and NBS1 IRIFs and inactive S phase checkpoint in MMR-defective and MRE11 mutated CRC cell lines (Giannini et al., 2002) . It is now well established that the MNR complex plays a pivotal role in protecting eukaryotic cells from the deleterious effect of DNA-DSB generated either in response to DNA injury (i.e. g-irradiation) or during DNA replication (D'Amours and Jackson, 2002). Thus, MRE11, NBS1 and RAD50 belong to the 'caretakers', a class of molecules known to be a relevant target for carcinogenesis. Indeed, mutations in NBS1 and MRE11 have also been described in MMR-proficient tumors (Fukuda et al., 2001; Varon et al., 2001; Tessitore et al., 2003) and the generation of mice-bearing hypomorphic mutation of NBS1 and RAD50 proved that perturbation of the activity of the complex might increase genome instability and predispose to cancer (Bender et al., 2002; Kang et al., 2002) . Thus, we think that the mutation we described fulfills all requirements to define MRE11 as a real 'target' gene in MMR-defective cancer.
Based on our results it seems that the biallelic shortening of one or two bases of the MRE11 Poly(T)11 MRE11 is a common target in MSI cancer G Giannini et al is associated to MNR function impairment. The question remains on the significance of milder mutations. Monoallelic frameshift mutations have been described in MMR-defective CRC for a number of DNA repair genes, including RAD50, BLM, MSH6, MSH3 and, although more rarely, BRCA1 and ATM (Kim et al., 2001; . Thus, the possibility exists that haploinsufficiency at several loci might lead to a dosage defect of multiple gene products operating on the same pathway and in turn to uncontrolled surveillance on growth or DNA stability. Further effort will be required to test this hypothesis.
Looking at the possible correlations between MRE11 mutations and the conventional clinical-pathological parameters, we found no differences in the frequencies associated with gender and tumor grading, while we found only a slightly higher frequency among familial compared to sporadic cases. In contrast, we observed very high frequencies in cases with advanced age and nonmetastatic presentation (A þ B stages) at diagnosis. Furthermore, low-grade (G1 and G2) tumors showed higher frequencies of MRE11 biallelic and thus inactivating mutations compared to high-grade tumors. The significance of these findings is unclear at the moment, but might suggest that the carcinogenetic pathways involving MRE11 inactivation might be associated to less aggressive phenotypes in CRC. Analysis of the survival of CRC patients with fully inactivating mutations of MRE11 will help to elucidate this matter. Likewise, the meaning and the preferential occurrence of MRE11 mutations in other proximal colonic locations compared to cecum, the higher incidence of biallelic mutation in familial compared to sporadic cases and in colorectal compared to endometrial cancer need to be elucidated.
In conclusion, this study demonstrated that although located in an intronic repeat, mutations of the MRE11 poly(T)11 due to defective MMR cause production of the 484del88 aberrant transcript and impairment of wild-type MRE11 expression in primary human MMRdefective cancer. Decreased or absent expression of MNR complex components may be detected by immunohistochemistry on tumor sections, thus suggesting that functionally significant MRE11 mutations might be directly searched for by this method in MMR-defective cancer. The high frequency of MRE11 mutation leading to inactivation of the MNR complex and the observation that perturbation of the MNR complex predisposes to cancer in animal models (Bender et al., 2002; Kang et al., 2002) highlight MRE11 as a new target gene for inactivation by MMR defects, and suggest its role in MMR-dependent colorectal carcinogenesis.
Materials and methods
Tissue and DNA specimens
From the tumor banks of our institutions, we collected 49 CRC samples, previously classified as MSI high type using the Bethesda panel of microsatellite loci (Boland et al., 1998) . With the exception of a colonic benign adenomatous polyp, all others were carcinomas. DNA was extracted by the DNAeasy tissue kit (Qiagen GmbH, Germany) from paraffin-embedded tissue previously dissected by a pathologist. Normal tissue and/or blood from 40 out of the 49 CRC patients were available for DNA extraction and analysis. Furthermore, a total of 62 DNAs from MMR-proficient CRC primary tumors and cell lines were included in this study as controls. In all cases, DNA quality was confirmed by the PCR amplification of the targets of the Bethesda panel and the GAPDH and or bactin gene. Conventional clinical-pathological data (sex, age of tumor onset, site, stage, grading) available for most, but not all cases, were collected by consultation of medical and pathological reports. Family history was investigated by patient interview. Of the 18 patients with positive CRC familial history, 12 were carriers of a constitutional MLH1 or MSH2 mutation. Endometrium (14), ovary (five), ureter (one) and stomach (one) primary cases previously classified as MSI were also included in this study. At the time of tumor resection, an informed consent for the employment of the specimens for research purposes was obtained from all patient/patient relatives. The Ethics committee of University La Sapienza approved our study protocol.
Statistical analysis
A two-tailed w 2 test or, when appropriate, a Fisher's exact test were used to compare categorical data (Fleiss, 1981) . The 'Mutated' parameter includes samples in which any type of MRE11 poly(T)11 shortening was detected. The 'Biallelic Mut.' parameter includes samples that failed to show the presence of the MRE11 WT Poly(T)11, and thus are surely mutated on both alleles. The statistical analyses were performed using the SAS language program (Version 8.2, SAS Institute Inc., Cary, NC, USA).
Cell lines and DNA, RNA and protein preparation and analysis CRC cell lines were grown in DMEM medium supplemented with 10% fetal bovine serum, glutamine and antibiotics. DNA was extracted by the Qiamp DNA Blood kit (Qiagen GmbH, Germany). A 122 bp DNA fragment containing the MRE11 polyT(11) and the RAD50 coding repeat was PCR amplified and sequenced as previously described (Giannini et al., 2002) . For RNA preparation, cells were scraped from the dish, washed twice with ice-cold PBS and processed for RNA extraction with the RNAeasy kit (Qiagen GmbH, Germany), according to the manufacturer's instructions. RNA extraction from frozen bulk tumor tissue was performed by means of TRIzol reagent (Gibco-BRL). For real-time quantitative RT-PCR, RNA (1 mg) was reversed transcribed using M-MLV reverse transcriptase (Invitrogen, San Diego, CA, USA), according to the manufacturer's instruction. In all, 1/10 of the reaction was PCR amplified, using standard PCR Master Mix (Applied Biosystems, Warrington, UK) and two different primer sets for the wild-type MRE11 transcript (Set 1, 5/6F: 5 0 -CAGTGTTTAGTATTCATGGCAATCATG-3 0 ; 5/6R: 5 0 -AATGTCCAAGGCACAAAGTGC-3 0 ; Set 2, 4Fext: 5 0 -GTG ATCAGTCAGTCAACTTTGGTTTTAG-3 0 ; 6Rext: 5 0 -ACA AATCCAGCACAACTTAAAATGTC-3 0 ) and specifically quantified in both cases with a TET-labeled probe (Probe 5/ 6: 5 0 -TET-CGATCCCACAGGGGCAGA-MGB) through a standard TaqMan approach. Amplification of both GAPDH and b-actin with specific primer sets and probes (Applied Biosystems, Warrington, UK) were performed for normalization under similar conditions on the same reverse transcription samples. The amplification procedure was monitored and analysed with an ABI Prism 7700 sequence detector (Applied Biosystems, Foster City, CA, USA). Protein extraction and Western blots were performed as previously described (Giannini et al., 2002) .
Immunohistochemistry
Upon a preliminary analysis of hematoxylin-eosin stained slides, six MMR-defective CRC cases severely mutated in the MRE11 poly(T)11 were selected for immunohistochemical studies, based on the coexistence of normal and neoplastic tissue in the same tissue section and on the absence of extensive tumor necrosis. The cases were representative of benign lesions (adenomatous polyp, one), moderately differentiated (G2) adenocarcinomas (four) and metastatic adenocarcinomas (liver metastasis, one). Immunohistochemistry was performed using the monoclonal antibodies 12D7 to MRE11 (ab214, Abcam, Cambridge, UK) and 1C3 anti-hp95/ nibrin/NBS1 (MS-NBS10-PX1, Abcam, Cambridge, UK) at 1 : 100 dilution. Incubation with the primary antibody was preceded by microwave treatment of the tissue section for antigen retrieval.
